Marinus Pharmaceuticals (MRNS)
(Delayed Data from NSDQ)
$1.30 USD
-0.02 (-1.52%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Marinus Pharmaceuticals (MRNS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.63 | $15.00 | $2.00 | 478.03% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Marinus Pharmaceuticals comes to $7.63. The forecasts range from a low of $2.00 to a high of $15.00. The average price target represents an increase of 478.03% from the last closing price of $1.32.
Analyst Price Targets (8 )
Broker Rating
Marinus Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.60 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.55 a month ago based on 11 recommendations.
Of the 10 recommendations deriving the current ABR, seven are Strong Buy, representing 70% of all recommendations. A month ago, Strong Buy represented 72.73%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/MRNS.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 8 | 8 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 4 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.60 | 1.73 | 1.55 | 1.55 | 1.55 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/14/2024 | Not Identified | Not Identified | Hold | Hold |
8/13/2024 | Not Identified | Not Identified | Hold | Hold |
7/9/2024 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
6/18/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
6/18/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
4/16/2024 | Robert W. Baird & Co. | Brian P Skorney | Strong Buy | Hold |
4/1/2024 | Cowen & Co. | Joseph Thome | Strong Buy | Strong Buy |
3/26/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
3/6/2024 | JMP Securities | Jason N Butler | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.60 |
ABR (Last week) | 1.73 |
# of Recs in ABR | 10 |
Average Target Price | $7.63 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 96 of 253 |
Current Quarter EPS Est: | -0.45 |